Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Citalopram Clear all
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of Medication With or Without Psychotherapy for Complicated Grief

NCT01179568
View directory record Official record
Conditions
Complicated Grief, Bereavement
Interventions
Citalopram, Complicated Grief Treatment, Placebo
Drug · Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 4 Interventional Results available

Contact: Developing New Clinical Management Strategies

NCT03812588
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

NCT02516332
View directory record Official record
Conditions
Anxiety, Cardiovascular Disease
Interventions
Lexapro, Placebo, Supervised Aerobic Exercise
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 4 Interventional Results available

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

NCT01557946
View directory record Official record
Conditions
MDD, Citalopram, Major Depressive Disorder
Interventions
citalopram
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 17, 2026, 1:06 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 17, 2026, 1:06 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 1:06 AM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Identifying Factors That Predict Antidepressant Treatment Response

NCT00360399
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Duloxetine, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 17, 2026, 1:06 AM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Enhanced Motor Recovery Using Serotonergic Agents in Stroke

NCT01751854
View directory record Official record
Conditions
Patients With Chronic Stroke
Interventions
SSRI, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 1:06 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Blinded capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram

NCT00613470
View directory record Official record
Conditions
Depression
Interventions
citalopram and escitalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

NCT00562861
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
citalopram + mood stabilizer, placebo + mood stabilizer
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 3 Interventional

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390650
View directory record Official record
Conditions
Anxiety
Interventions
Saredutant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Escitalopram, JNJ-18038683
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 17, 2026, 1:06 AM EDT
Terminated Phase 4 Interventional Results available

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

NCT00523705
View directory record Official record
Conditions
PMS
Interventions
escitalopram, placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 19 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168
View directory record Official record
Conditions
Parkinson Disease
Interventions
Citalopram 20mg, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 1:06 AM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

NCT02579343
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Auricular Acupuncture, Sham Auricular Acupuncture + Lexapro
Device · Drug
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 17, 2026, 1:06 AM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Treating Behavioral Disturbances in Individuals With Dementia

NCT00073658
View directory record Official record
Conditions
Dementia
Interventions
Citalopram, Risperidone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 17, 2026, 1:06 AM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 17, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

NCT00358631
View directory record Official record
Conditions
Depressive Disorder
Interventions
SSR149415
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Oct 17, 2026, 1:06 AM EDT